NASDAQ:NVTR - Nuvectra Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nuvectra Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.11 0.00 (0.00 %) (As of 02/21/2020 04:00 PM ET) Add Compare Today's Range$0.10Now: $0.11▼$0.1250-Day Range$0.11MA: $0.14▼$0.2152-Week Range$0.13Now: $0.11▼$20.85Volume74,205 shsAverage Volume2.43 million shsMarket Capitalization$2.04 millionP/E RatioN/ADividend YieldN/ABeta0.69 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs. It is also developing Virtis, a sacral neuromodulation (SNM) system for the treatment of chronic urinary retention and overactive bladder; and technologies to support other indications, including SNM for the treatment of overactive bladder and deep brain stimulation to treat Parkinson's disease. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVTR Previous SymbolNASDAQ:NVTRV CUSIPN/A CIK1648893 Webhttp://www.nuvectramed.com/ Phone214-474-3103Debt Debt-to-Equity Ratio0.58 Current Ratio4.86 Quick Ratio4.42Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$48.83 million Price / Sales0.04 Cash FlowN/A Price / Cash FlowN/A Book Value$5.28 per share Price / Book0.02Profitability EPS (Most Recent Fiscal Year)($3.19) Net Income$-48,130,000.00 Net Margins-99.08% Return on Equity-58.23% Return on Assets-34.01%Miscellaneous Employees197 Outstanding Shares17,890,000Market Cap$2.04 million Next Earnings DateN/A OptionableOptionable Receive NVTR News and Ratings via Email Sign-up to receive the latest news and ratings for NVTR and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:NVTR Rates by TradingView Nuvectra (NASDAQ:NVTR) Frequently Asked Questions What is Nuvectra's stock symbol? Nuvectra trades on the NASDAQ under the ticker symbol "NVTR." How were Nuvectra's earnings last quarter? Nuvectra Corp (NASDAQ:NVTR) announced its quarterly earnings results on Monday, October, 29th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by $0.01. The business had revenue of $14.22 million for the quarter, compared to the consensus estimate of $12.38 million. Nuvectra had a negative return on equity of 58.23% and a negative net margin of 99.08%. View Nuvectra's Earnings History. What price target have analysts set for NVTR? 3 Wall Street analysts have issued twelve-month price objectives for Nuvectra's shares. Their forecasts range from $4.00 to $18.00. On average, they anticipate Nuvectra's stock price to reach $10.67 in the next year. This suggests a possible upside of 9,264.9% from the stock's current price. View Analyst Price Targets for Nuvectra. What is the consensus analysts' recommendation for Nuvectra? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvectra in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nuvectra. Has Nuvectra been receiving favorable news coverage? News headlines about NVTR stock have been trending very positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Nuvectra earned a news impact score of 3.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Nuvectra. Who are some of Nuvectra's key competitors? Some companies that are related to Nuvectra include PlusTherapeuticsInc . (PSTV), Encision (ECIA), CELLECT BIOTECH/S (APOP), Cytocore (MDIT), AdvanSource Biomaterials Corpration (ASNB), Invivo Therapeutics (NVIV), Neurometrix (NURO), Regenicin (RGIN), Sintx Technologies (SINT), United American Healthcare (UAHC), Hypertension Diagnostics (HDII), Valeritas (VLRX), TearLab (TEAR), Calmare Therapeutics (CTTC) and Lombard Medical (EVARF). What other stocks do shareholders of Nuvectra own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nuvectra investors own include Allena Pharmaceuticals (ALNA), NovaBay Pharmaceuticals (NBY), Aldeyra Therapeutics (ALDX), Avinger (AVGR), Biocept (BIOC), Deciphera Pharmaceuticals (DCPH), Fate Therapeutics (FATE), Iovance Biotherapeutics (IOVA), Rigel Pharmaceuticals (RIGL) and Ampliphi Biosciences (APHB). Who are Nuvectra's key executives? Nuvectra's management team includes the folowing people: Dr. Fred B. Parks Ph.D., CEO & Director (Age 72)Mr. Joseph Paul Hanchin, Pres (Age 57)Mr. Walter Z. Berger, COO, CFO & Exec. VP (Age 63)Ms. Jennifer J. Kosharek, VP, Controller & Principal Accounting Officer (Age 38)Mr. Benjamin Tranchina, Chief Technology Officer How do I buy shares of Nuvectra? Shares of NVTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Nuvectra's stock price today? One share of NVTR stock can currently be purchased for approximately $0.11. How big of a company is Nuvectra? Nuvectra has a market capitalization of $2.04 million and generates $48.83 million in revenue each year. The company earns $-48,130,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Nuvectra employs 197 workers across the globe.View Additional Information About Nuvectra. What is Nuvectra's official website? The official website for Nuvectra is http://www.nuvectramed.com/. How can I contact Nuvectra? Nuvectra's mailing address is 5830 GRANITE PKWY SUITE 1100, PLANO TX, 75024. The company can be reached via phone at 214-474-3103 or via email at [email protected] MarketBeat Community Rating for Nuvectra (NASDAQ NVTR)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 245 (Vote Outperform)Underperform Votes: 236 (Vote Underperform)Total Votes: 481MarketBeat's community ratings are surveys of what our community members think about Nuvectra and other stocks. Vote "Outperform" if you believe NVTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/22/2020 by MarketBeat.com StaffFeatured Article: What sectors are represented in the Nikkei Index?
